药物不良反应杂志
藥物不良反應雜誌
약물불량반응잡지
ADVERSE DRUG REACTIONS JOURNAL
2014年
5期
313-314
,共2页
孙敏%曹凯%胡宝祥%司继刚
孫敏%曹凱%鬍寶祥%司繼剛
손민%조개%호보상%사계강
血糖%环孢素
血糖%環孢素
혈당%배포소
Blood glucose%Cyclosporine
1例27岁女性患者因白细胞减少症和血小板减少症给予口服司坦唑醇(2 mg,3次/d)、再造升血片(4片,3次/d ),皮下注射非格司亭(150μg,1次/d )、重组人白细胞介素11(2 mg,1次/d)、重组人促红素(10000 U,3次/周),静脉滴注头孢美唑(2 g,2次/d),以及成分输血等治疗。用药前空腹血糖5.3 mmol/L。18 d后诊断为再生障碍性贫血,加用环孢素125 mg,2次/d口服。加药第28天,患者空腹血糖升至9.8 mmol/L,予饮食控制。第36天,空腹血糖8.2 mmol/L。第45天,空腹血糖达10.7 mmol/L,餐后2 h血糖为18.7 mmol/L,将环孢素剂量改为100 mg,2次/d,并加用二甲双胍500 mg,2次/d口服,且严格执行糖尿病饮食。第47天,空腹血糖7.3 mmol/L;第55天,空腹血糖5.4 mmol/L,餐后2 h血糖11.3 mmol/L。
1例27歲女性患者因白細胞減少癥和血小闆減少癥給予口服司坦唑醇(2 mg,3次/d)、再造升血片(4片,3次/d ),皮下註射非格司亭(150μg,1次/d )、重組人白細胞介素11(2 mg,1次/d)、重組人促紅素(10000 U,3次/週),靜脈滴註頭孢美唑(2 g,2次/d),以及成分輸血等治療。用藥前空腹血糖5.3 mmol/L。18 d後診斷為再生障礙性貧血,加用環孢素125 mg,2次/d口服。加藥第28天,患者空腹血糖升至9.8 mmol/L,予飲食控製。第36天,空腹血糖8.2 mmol/L。第45天,空腹血糖達10.7 mmol/L,餐後2 h血糖為18.7 mmol/L,將環孢素劑量改為100 mg,2次/d,併加用二甲雙胍500 mg,2次/d口服,且嚴格執行糖尿病飲食。第47天,空腹血糖7.3 mmol/L;第55天,空腹血糖5.4 mmol/L,餐後2 h血糖11.3 mmol/L。
1례27세녀성환자인백세포감소증화혈소판감소증급여구복사탄서순(2 mg,3차/d)、재조승혈편(4편,3차/d ),피하주사비격사정(150μg,1차/d )、중조인백세포개소11(2 mg,1차/d)、중조인촉홍소(10000 U,3차/주),정맥적주두포미서(2 g,2차/d),이급성분수혈등치료。용약전공복혈당5.3 mmol/L。18 d후진단위재생장애성빈혈,가용배포소125 mg,2차/d구복。가약제28천,환자공복혈당승지9.8 mmol/L,여음식공제。제36천,공복혈당8.2 mmol/L。제45천,공복혈당체10.7 mmol/L,찬후2 h혈당위18.7 mmol/L,장배포소제량개위100 mg,2차/d,병가용이갑쌍고500 mg,2차/d구복,차엄격집행당뇨병음식。제47천,공복혈당7.3 mmol/L;제55천,공복혈당5.4 mmol/L,찬후2 h혈당11.3 mmol/L。
A 27-year-old female patient received oral stanozolol 2 mg thrice daily and 4 Zaizao Shengxue tablets(再造升血片)thrice daily,subcutaneous injection of filgrastim 150 μg once daily, recombinant human interleukin-11 2 mg once daily,and recombinant human erythropoietin 10 000 U thrice weekly,and an intravenous infusion of cefmetazole 2 g twice daily combined with supportive treatment of blood component transfusion for leukopenia and thrombopenia. Her fasting blood glucose was 5. 3 mmol/L before the medication. Eighteen days later,aplastic anemia was diagnosed and oral cyclosporine 125 mg twice daily was added to the regimen. On day 28 of adding cyclosporine,the level of fasting plasma glucose increased to 9. 8 mmol/L and the patient's diet restricted. On day 36,the level of fasting plasma glucose was 8. 2 mmol/L. On day 45,the level of fasting plasma glucose and 2-hour post-meal blood glucose were respectively 10. 7 mmol/L and 18. 7 mmol/L. The dose of cyclosporine was adjusted to 100 mg twice daily and diabetic diet was given strictly. On day 47,the level of fasting plasma glucose was 7. 3 mmol/L and on day 55,the level of fasting plasma glucose was 5. 4 mmol/L and the 2-hour post-meal blood glucose was 11. 3 mmol/L.